Abstract
We tested the hypothesis that exogenous administration of the ET-1 precursor, bigET-1, would regulate adult rat ventricular myocyte (ARVM) contractility in a p38-mitogen activated protein kinase (p38-MAPK)-dependent mechanism during sepsis. Ventricular myocytes from adult rat hearts (both sham and septic) were stimulated to contract at 0.5 Hz and mechanical properties were evaluated using an IonOptix Myocam system. Immunoblot analysis was used to determine the phosphorylation of p38-MAPK and extracellular signal-regulated kinase 1/2 (ERK1/2). ARVMs were treated with vehicle, bigET-1 and inhibitors for 24 h and then subjected to functional and biochemical estimations. Septic ARVM displayed a distorted cell membrane and irregular network within the cells along with increased cell contractility as evidenced by elevated peak shortening (PS), maximal velocity of shortening (+dL/dt) and relengthening (-dL/dt) in comparison to sham ARVM. BigET-1 treatment caused ARVM enlargement in both sham and sepsis groups. BigET-1 (100 nM) produced an increase in ARVM contractility in sham group as compared to vehicle treatment. However, septic ARVM treated with bigET-1 exhibited unaltered ARVM contractility, and upregulated ET B receptors as compared to respective sham group. BigET-1 increased the concentration of ET-1 and upregulated phosphorylation of p38-MAPK but not of ERK1/2 in sham and septic ARVM. Furthermore, inhibition of p38-MAPK by SB203580 (10 μM) increased ARVM contractility in sham but not in sepsis group. BigET-1 reversed SB203580-induced increase in PS in sham group but accentuated it in sepsis group. BigET-1 also reversed SB203580-induced inhibition of p38-MAPK phosphorylation in sham but not in septic ARVM. SB203580 pretreatment followed by bigET-1 administration significantly decreased p38-MAPK phosphorylation and downregulated ET B receptor expression as compared to bigET-1 treatment per se in sepsis group but not in sham. We concluded that a bigET-1-induced non-responsive effect on septic ARVM contractile function could be due to upregulation of p38-MAPK phosphorylation and ET B receptor expression. © 2005 Elsevier B.V. All rights reserved.
Original language | American English |
---|---|
Journal | Biochimica et Biophysica Acta - Molecular Basis of Disease |
Volume | 1741 |
State | Published - Jan 1 2005 |
Keywords
- 2 (2 amino 3 methoxyphenyl)chromone
- 4 (4 fluorophenyl) 2 (4 methylsulfinylphenyl) 5 (4 pyridyl)imidazole
- Adult rat ventricular myocyte
- Animals
- Cardiac
- ERK1/2
- Endothelin-1
- Heart Ventricles
- Immunoblot analysis
- Myocardial Contraction
- Myocytes
- Peak shortening
- Rats
- Sprague-Dawley
- animal cell
- animal experiment
- animal model
- article
- bigendothelin 1
- cell damage
- cell membrane
- cell viability
- controlled study
- endothelin 1
- endothelin 1 derivative
- endothelin A receptor
- endothelin B receptor
- enzyme inhibition
- enzyme phosphorylation
- heart muscle cell
- heart ventricle contractility
- male
- mitogen activated protein kinase 1
- mitogen activated protein kinase 3
- mitogen activated protein kinase p38
- mitogen activated protein kinase p38 inhibitor
- nonhuman
- p38 -MAPK
- p38 Mitogen-Activated Protein Kinases
- priority journal
- protein expression
- rat
- regulatory mechanism
- sepsis
- unclassified drug
- upregulation
Disciplines
- Life Sciences